Filing Analysis
ImmuCell Corporation announced a significant board refresh involving the resignation of three directors and the appointment of two new members with deep industry expertise. The departures include former long-time CEO Michael Brigham and current VP of Sales Bobbi Jo Brockmann, effective April 15, 2026.
Red Flags
- Simultaneous departure of three board members, representing a significant loss of institutional knowledge.
- Departure of the former long-term CEO from the board less than a year after his retirement as CEO.
Key Facts
- Three directors (Bryan K. Gathagan, Michael F. Brigham, and Bobbi Jo Brockmann) are resigning or retiring from the Board effective April 15, 2026.
- Michael F. Brigham served as President and CEO for over 25 years (2000-2025) and has been a director since 1999.
- Bobbi Jo Brockmann will remain the Company’s Vice President of Sales and Marketing despite resigning from the Board.
- New director Gilles Guillemette, DVM, brings 30+ years of experience from Elanco, Bayer, and Trupanion.
- New director Anthony DiMarco, Ph.D., brings 21 years of experience from IDEXX as VP of R&D and Global Manufacturing.
- A new Strategy & Technology Committee has been formed, which both new directors will join.
ImmuCell Corporation announced preliminary unaudited sales results for the first quarter of 2026, reporting a 28.4% increase in product sales compared to the first quarter of 2025. The disclosure was made via a press release on April 8, 2026, following the close of the quarter on March 31, 2026.
Key Facts
- Preliminary unaudited product sales for Q1 2026 increased by 28.4% compared to Q1 2025.
- The reporting period ended March 31, 2026.
- The filing was made under Item 2.02 (Results of Operations and Financial Condition).
- The report was signed by Timothy C. Fiori, Chief Financial Officer.
ImmuCell Corporation announced that director Steven A. Rosgen will retire from the Board effective April 1, 2026, following a previous notice of non-reelection. Kathy V. Turner, a former executive at IDEXX Laboratories and Abbott Laboratories, has been elected to fill the vacancy and will chair the Compensation and Stock Option Committee.
Key Facts
- Steven A. Rosgen tendered his resignation on March 12, 2026, effective April 1, 2026.
- Kathy V. Turner was elected to the Board effective April 1, 2026.
- Ms. Turner will serve on the Audit Committee and as Chair of the Compensation and Stock Option Committee.
- Ms. Turner brings over 30 years of experience, including roles as Chief Marketing Officer at IDEXX Laboratories and leadership positions at Abbott Laboratories.
- The transition was previously signaled in an 8-K filed on February 9, 2026.
ImmuCell Corporation announced its unaudited financial results for the fourth quarter and full fiscal year ended December 31, 2025. The disclosure was made via a press release furnished as an exhibit to the filing.
Key Facts
- The filing was made on March 4, 2026, reporting on the period ended December 31, 2025.
- The report includes both quarterly and full-year unaudited financial results.
- The information is furnished under Item 2.02 and is not deemed 'filed' for purposes of Section 18 of the Exchange Act.
- Timothy C. Fiori, CFO, signed the report.